Physician profile
Sofia Miranda
NPI 1093003220
$66,546.45
in general payments reported to CMS, 2019-2025
22 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13K · 2022: $3,031 · 2023: $13K · 2024: $26K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Travel and Lodging: $12K · Consulting Fee: $11K · Food and Beverage: $3,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,153.02 |
| Travel and Lodging | $12,483.43 |
| Consulting Fee | $10,595.25 |
| Food and Beverage | $3,613.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $40,272.57 | 2021-2025 | |
| Genentech USA, INC. | $11,755.91 | 2021-2025 | Hemlibra |
| Novo Nordisk INC | $5,470.94 | 2023-2025 | Novoeight, Rebinyn, Novoseven |
| Pfizer INC. | $4,602.32 | 2023-2025 | |
| Octapharma USA, INC. | $2,764.74 | 2022 | |
| Merz Pharmaceuticals, LLC | $490.13 | 2022-2024 | Xeomin |
| Alexion Pharmaceuticals, INC. | $173.67 | 2023-2024 | Soliris, Koselugo |
| Tanabe Pharma America, INC. | $145.34 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.00 | 2022-2025 | |
| Sobi, INC | $101.43 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $99.93 | 2022-2023 | Ingrezza, Ongentys |
| Janssen Pharmaceuticals, INC | $91.94 | 2022 | |
| Astellas Pharma US INC | $86.54 | 2024-2025 | Cresemba |
| Takeda Pharmaceuticals U.S.A., INC. | $69.97 | 2023-2025 | Vpriv, Vonvendi |
| Novartis Pharmaceuticals Corporation | $59.55 | 2022-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genetix Biotherapeutics INC | $51.56 | 2024 | |
| Biomarin Pharmaceutical INC. | $46.47 | 2023-2024 | Roctavian, Roctavian |
| Rare Disease Therapeutics, INC. | $41.01 | 2024-2025 | Purixan, Xromi |
| Hema Biologics, LLC | $39.27 | 2025 | Sevenfact |
| Agios Pharmaceuticals, INC. | $36.14 | 2024 | Pyrukynd |
| Recordati_rare_diseases_inc. | $16.45 | 2024 | Panhematin |
| Btg International INC. | $15.57 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Miranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.